JP2009520754A5 - - Google Patents

Download PDF

Info

Publication number
JP2009520754A5
JP2009520754A5 JP2008546388A JP2008546388A JP2009520754A5 JP 2009520754 A5 JP2009520754 A5 JP 2009520754A5 JP 2008546388 A JP2008546388 A JP 2008546388A JP 2008546388 A JP2008546388 A JP 2008546388A JP 2009520754 A5 JP2009520754 A5 JP 2009520754A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
tumor
hydrogen
leukemia
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008546388A
Other languages
English (en)
Japanese (ja)
Other versions
JP5657205B2 (ja
JP2009520754A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/069666 external-priority patent/WO2007071603A1/en
Publication of JP2009520754A publication Critical patent/JP2009520754A/ja
Publication of JP2009520754A5 publication Critical patent/JP2009520754A5/ja
Application granted granted Critical
Publication of JP5657205B2 publication Critical patent/JP5657205B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008546388A 2005-12-21 2006-12-13 薬物耐性腫瘍の治療 Expired - Fee Related JP5657205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027997.5 2005-12-21
EP05027997 2005-12-21
PCT/EP2006/069666 WO2007071603A1 (en) 2005-12-21 2006-12-13 Treatment of drug-resistant tumors

Publications (3)

Publication Number Publication Date
JP2009520754A JP2009520754A (ja) 2009-05-28
JP2009520754A5 true JP2009520754A5 (enExample) 2010-01-28
JP5657205B2 JP5657205B2 (ja) 2015-01-21

Family

ID=35911064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008546388A Expired - Fee Related JP5657205B2 (ja) 2005-12-21 2006-12-13 薬物耐性腫瘍の治療

Country Status (19)

Country Link
US (1) US7888368B2 (enExample)
EP (1) EP1962850B1 (enExample)
JP (1) JP5657205B2 (enExample)
KR (1) KR101366868B1 (enExample)
CN (1) CN101340910B (enExample)
AT (1) ATE548038T1 (enExample)
AU (1) AU2006328607B2 (enExample)
BR (1) BRPI0620209A2 (enExample)
CA (1) CA2631868C (enExample)
CY (1) CY1112814T1 (enExample)
DK (1) DK1962850T3 (enExample)
EA (1) EA016487B1 (enExample)
ES (1) ES2382819T3 (enExample)
HR (1) HRP20120359T1 (enExample)
PL (1) PL1962850T3 (enExample)
PT (1) PT1962850E (enExample)
RS (1) RS52272B (enExample)
SI (1) SI1962850T1 (enExample)
WO (1) WO2007071603A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853233B2 (en) * 2007-02-13 2014-10-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
WO2009015981A2 (en) * 2007-08-01 2009-02-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of pediatric tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung

Similar Documents

Publication Publication Date Title
TW518223B (en) Antitumour synergistic composition
JP2006503919A5 (enExample)
CN102395372B (zh) 用于治疗造血组织肿瘤和白血病的苯并二氮*衍生物
RU2012153963A (ru) Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
JP2006523216A5 (enExample)
JP2012067116A5 (enExample)
TW201228661A (en) Pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells and uses of the same
JP2007529421A5 (enExample)
JP2008536807A5 (enExample)
CN101478968A (zh) 具有新的“触发”内酯稳定的e环的喜树碱类似物及其制备和使用方法
CN104582708A (zh) 用于治疗小细胞肺癌的苯并二氮*类
JP2002507571A (ja) アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
JP2009515901A5 (enExample)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2009536956A5 (enExample)
JP2006514681A5 (enExample)
JP2009520754A5 (enExample)
CA2448251A1 (en) Metal complexes and therapeutic uses thereof
CA2596084A1 (en) Treatment of metastasized tumors with quinolinone benzimidazole compounds
JP2011500841A5 (enExample)
ES2286280T3 (es) Utilizacion de sustancias activas con un efecto agonista de receptores nu de opiodes y con un efecto antagonista de receptores de opiodes, como medicamentos combinados para el tratamiento de un cancer.
Kumar et al. Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms
Li et al. Research progress of compound injection of traditional Chinese medicine in the treatment of liver cancer
JP2007511492A5 (enExample)